Rogers Corporation designs, develops, manufactures, and sells engineered materials and components in the United States, Europe, and Asia. It operates through Advanced Electronics Solutions (AES), Elastomeric Material Solutions (EMS), and Other segments. The AES segment offers circuit materials, ceramic substrate materials, busbars, and cooling solutions for applications in electric and hybrid electric vehicles, wireless infrastructure, automotive, renewable energy, aerospace and defense, mass transit, industrial, connected devices, and wired infrastructure. This segment sells its products under the curamik, ROLINX, RO4000 Series, RO3000 Series, RT/duroid, CLTE Series, TMM, AD Series, DiClad Series, CuClad Series, Kappa, COOLSPAN, TC Series, IsoClad Series, MAGTREX, IM Series, 2929 Bondply, SpeedWave Prepreg, RO440/RO4400T Series, and Radix names. The EMS segment provides engineered material solutions, including polyurethane and silicone materials used in cushioning, gasketing, sealing, and vibration management applications; customized silicones used in flex heater and semiconductor thermal applications; and polytetrafluoroethylene and ultra-high molecular weight polyethylene materials used in wire and cable protection, electrical insulation, conduction and shielding, hose and belt protection, vibration management, cushioning, gasketing and sealing, and venting applications. This segment sells its products under the PORON, BISCO, DeWAL, ARLON, eSorba, XRD, Silicone Engineering, and R/bak names. The Other segment provides elastomer components; and elastomer floats for level sensing in fuel tanks, motors, and storage tanks for applications in the general industrial and automotive markets under the ENDUR and NITROPHYL names. The company was founded in 1832 and is headquartered in Chandler, Arizona.
Roche's Crossroads | Explore Roche's strategic position as it navigates challenges in the obesity treatment market while leveraging its strengths in diagnostics innovation |
Financial Headwinds | Analysts project a -3.1% profit decline year-over-year, with EPS estimates of 18.76 for FY1 and 20.21 for FY2, reflecting a cautious market outlook |
Competitive Landscape | Delve into Roche's efforts to differentiate its obesity treatments in a market dominated by established players, facing tolerability hurdles and fierce competition |
Future Prospects | Learn about Roche's potential in the growing obesity treatment market and its diagnostics sector, with analyst price targets ranging from CHF 272.3 to CHF 275.00 |
Metrics to compare | ROG | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipROGPeersSector | |
---|---|---|---|---|
P/E Ratio | 55.6x | −44.5x | 11.4x | |
PEG Ratio | −1.03 | −0.84 | 0.01 | |
Price/Book | 1.2x | −18.3x | 2.4x | |
Price / LTM Sales | 1.7x | 2.9x | 2.1x | |
Upside (Analyst Target) | 46.7% | 53.2% | 28.6% | |
Fair Value Upside | Unlock | −14.2% | 6.3% | Unlock |